全文获取类型
收费全文 | 1407篇 |
免费 | 121篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 59篇 |
妇产科学 | 17篇 |
基础医学 | 168篇 |
口腔科学 | 52篇 |
临床医学 | 119篇 |
内科学 | 250篇 |
皮肤病学 | 34篇 |
神经病学 | 77篇 |
特种医学 | 280篇 |
外科学 | 96篇 |
综合类 | 43篇 |
一般理论 | 2篇 |
预防医学 | 153篇 |
眼科学 | 18篇 |
药学 | 79篇 |
中国医学 | 3篇 |
肿瘤学 | 95篇 |
出版年
2019年 | 11篇 |
2018年 | 17篇 |
2017年 | 16篇 |
2016年 | 16篇 |
2015年 | 12篇 |
2014年 | 24篇 |
2013年 | 38篇 |
2012年 | 36篇 |
2011年 | 40篇 |
2010年 | 44篇 |
2009年 | 39篇 |
2008年 | 57篇 |
2007年 | 42篇 |
2006年 | 45篇 |
2005年 | 24篇 |
2004年 | 32篇 |
2003年 | 27篇 |
2002年 | 26篇 |
2001年 | 39篇 |
2000年 | 31篇 |
1999年 | 34篇 |
1998年 | 42篇 |
1997年 | 50篇 |
1996年 | 50篇 |
1995年 | 39篇 |
1994年 | 26篇 |
1993年 | 35篇 |
1992年 | 35篇 |
1991年 | 38篇 |
1990年 | 25篇 |
1989年 | 45篇 |
1988年 | 36篇 |
1987年 | 63篇 |
1986年 | 40篇 |
1985年 | 31篇 |
1984年 | 25篇 |
1983年 | 22篇 |
1982年 | 26篇 |
1981年 | 32篇 |
1980年 | 22篇 |
1979年 | 11篇 |
1978年 | 14篇 |
1977年 | 17篇 |
1976年 | 32篇 |
1975年 | 18篇 |
1974年 | 7篇 |
1973年 | 9篇 |
1972年 | 11篇 |
1971年 | 11篇 |
1970年 | 8篇 |
排序方式: 共有1550条查询结果,搜索用时 15 毫秒
21.
ATRX encodes a novel member of the SNF2 family of proteins: mutations point to a common mechanism underlying the ATR-X syndrome 总被引:11,自引:3,他引:11
Picketts DJ; Higgs DR; Bachoo S; Blake DJ; Quarrell OW; Gibbons RJ 《Human molecular genetics》1996,5(12):1899-1907
It was shown recently that mutations of the ATRX gene give rise to a
severe, X-linked form of syndromal mental retardation associated with alpha
thalassaemia (ATR-X syndrome). In this study, we have characterised the
full-length cDNA and predicted structure of the ATRX protein. Comparative
analysis shows that it is an entirely new member of the SNF2 subgroup of a
superfamily of proteins with similar ATPase and helicase domains. ATRX
probably acts as a regulator of gene expression. Definition of its genomic
structure enabled us to identify four novel splicing defects by screening
52 affected individuals. Correlation between these and previously
identified mutations with variations in the ATR-X phenotype provides
insights into the pathophysiology of this disease and the normal role of
the ATRX protein in vivo.
相似文献
22.
23.
24.
25.
An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT 总被引:43,自引:0,他引:43
N W Roehm G H Rodgers S M Hatfield A L Glasebrook 《Journal of immunological methods》1991,142(2):257-265
A new tetrazolium salt XTT, sodium 3'-[1-[(phenylamino)-carbonyl]-3,4-tetrazolium]-bis(4-methoxy-6- nitro)benzene-sulfonic acid hydrate, was evaluated for use in a colorimetric assay for cell viability and proliferation by normal activated T cells and several cytokine dependent cell lines. Cleavage of XTT by dehydrogenase enzymes of metabolically active cells yields a highly colored formazan product which is water soluble. This feature obviates the need for formazan crystal solubilization prior to absorbance measurements, as required when using other tetrazolium salts such as MTT. Bioreduction of XTT by all the murine cells examined was not particularly efficient, but could be potentiated by addition of electron coupling agents such as phenazine methosulfate (PMS) or menadione (MEN). Optimal concentrations of PMS or MEN were determined for the metabolism of XTT by the T cell lines HT-2 and 11.6, NFS-60 a myeloid leukemia, MC/9 a mast cell line and mitogen activated splenic T cells. When used in combination with PMS, each of these cells generated higher formazan absorbance values with XTT than were observed with MTT. Thus the use of XTT in colorimetric proliferation assays offer significant advantages over MTT, resulting from reduced assay time and sample handling, while offering equivalent sensitivity. 相似文献
26.
27.
Plant Antiviral Agents; VI.1 3-Methoxyflavones as Potent Inhibitors of Viral-Induced Block of Cell Synthesis 总被引:1,自引:0,他引:1
An investigation of the constituents responsible for the pronounced antiviral activity observed for extracts of EUPHORBIA GRANTII Oliv. stems has afforded four related 3-methoxyflavones exhibiting remarkable activities against picornaviruses and vesicular stomatitis virus. All compounds were found to be derivatives of 3-methylquercetin. The concentration of 3-methylquercetin (3-MQ) and 3,3'-dimethyl-quercetin (3,3'-DMQ) inhibiting 90 % of polio type 1 and coxsackie B4 viruses in tissue culture was about 0.01 microg/ml, whereas the 50 % cytotoxic concentration was 40 microg/ml. When administered intraperitoneally, 3-MQ protected mice from viremia and lethal infections from coxsac kie B4 virus at a daily dose of 20 mg/kg for a period of nine days. Biochemical studies on the mechanism of action of 3-MQ or 3,3'-DMQ on poliovirus replication suggested that these 3-methoxyflavones are able to protect the host cells from a viral induced shutdown of the cellular protein synthesis. Preliminary structure activity relationship studies have shown the 3-methoxyfunction of the flavones to be essential for the observed antiviral effects. 相似文献
28.
James N. Ingle MD Carl G. Kardinal Vera J. Suman James E. Krook Alan K. Hatfield 《Investigational new drugs》1996,14(2):235-237
Summary Octreotide is a synthetic somatostatin analogue which has shown inhibitory activity against human breast cancer cells in culture. Ten patients with metastatic breast cancer and no prior hormonal therapy exposure received octreotide at 150 g subcutaneously thrice daily. No objective responses were observed and the median time to treatment failure was short at 57 days. 相似文献
29.
30.
John R. Baldwin Barbara A. Phillips Stephen K. Overmyer Naomi Z. Hatfield Prem K. Narang 《Cancer chemotherapy and pharmacology》1992,30(6):433-438
Summary The influence of dexrazoxane on doxorubicin pharmacokinetics was investigated in four dogs using the two treatment sequences of saline/doxorubicin or dexrazoxane/doxorubicin. Intravenous doses of 1.5 mg/kg doxorubicin and 30 mg/kg (the 20-fold multiple) dexrazoxane were given separately, with doxorubicin being injected within 1 min of the dexrazoxane dose. Both doxorubicin and its 13-dihydro metabolite doxorubicinol were quantified in plasma and urine using a validated high-performance liquid chromatographic (HPLC) fluorescence assay. The doxorubicin plasma concentration versus time data were adequately fit by a three-compartment model. The mean half-lives calculated for the fast and slow distributive and terminal elimination phases in the saline/doxorubicin group were 3.0±0.5 and 32.2±12.8 min and 30.0±4.0 h, respectively. The model-predicted plasma concentrations were virtually identical for the saline and dexrazoxane treatment groups. Analysis of variance of the area under the plasma concentration-time curve (AUC0–), terminal elimination rate (Z), systemic clearance (CL
s), and renal clearance (CL
r) for the parent drug showed no statistically significant difference (P<0.05) between the two treatments. Furthermore, the doxorubicinol plasma AUC0– value and the doxorubicinol-to-doxorubicin AUC0– ratio showed no significant difference, demonstrating that dexrazoxane had no effect on the metabolic capacity for formation of the 13-dihydro metabolite. The total urinary excretion measured as parent drug plus doxorubicinol and the metabolite-to-parent ratio in urine were also unaffected by the presence of dexrazoxane. The myelosuppressive effects of doxorubicin as determined by WBC monitoring revealed no apparent difference between the two treatments. In conclusion, these results show that drug exposure was similar for the two treatment arms. No kinetic interaction with dexrazoxane suggests that its coadministration is unlikely to modify the safety and/or efficacy of doxorubicin. 相似文献